Abstract 3599
Background
Palbociclib, the first clinically available oral CDK4/6 inhibitor, in combination with endocrine therapy has become standard of care for HR+/HER2- advanced/metastatic breast cancer (MBC). No real-world studies have examined relative effectiveness of palbociclib plus endocrine therapy compared with endocrine therapy alone. This study compared real-world progression free survival (rwPFS) of palbociclib plus letrozole (PB+LE) vs letrozole alone (LE) for MBC in US routine clinical practices.
Methods
We conducted a retrospective analysis of MBC patients from the Flatiron Health longitudinal database, which contains electronic health records from 275 cancer clinics representing more than 2 million actively treated cancer patients in the US. Between February 2015 and August 2018, 1416 HR+/HER2– MBC women started PB+LE (n = 798) or LE (n = 618) as first-line therapy. Patients were evaluated from start of PB+LE or LE to November 2018, death, or last visit, whichever came first. rwPFS was defined as months from start of PB+LE or LE to death or disease progression based on clinical assessment or evidence by radiographic scan/tissue biopsy. 1:1 propensity score (PS) matching was used to balance patient characteristics.
Results
Of 1416 eligible patients, 906 were 1:1 PS matched (453 for each cohort). Median follow-up was 16.8 months, median age was 68.0 years, 70% were white, and 49.7% had visceral disease. Median rwPFS was 24.5 months (95%CI = 20.7 – 32.7) in PB+LE cohort and 17.1 months (95%CI=13.7—19.8) in LE cohort (HR = 0.68, 95%CI=0.56—0.84, p =.0003). Table presents key patient characteristics and landmark rwPFS rates.Table:
329P Patient characteristics and real-world progressionfree survival (rwPFS)
Variable | PB+LE (N = 453) | LE alone (N = 453) |
---|---|---|
Median age (years) | 68.0 | 68.0 |
White (%) | 69.8 | 70.6 |
Median number of metastatic sites (n) | 2.0 | 2.0 |
Bone only disease (%) | 26.9 | 32.2 |
Visceral disease (%) | 49.7 | 49.7 |
Median rwPFS, months (95%CI) | 24.5 (20.7—32.7) | 17.1 (13.7—19.8) |
rwPFS rate at 6 months (%) | 82.8 | 74.5 |
rwPFS rate at 12 months (%) | 72.1 | 58.9 |
rwPFS rate at 18 months (%) | 60.1 | 48.4 |
rwPFS rate at 24 months (%) | 50.2 | 39.1 |
Median follow-up, months (IQR) | 16.8(8.1—27.1) | 16.8(6.9—26.9) |
PB+LE = Palbociclib plus letrozole; LE = Letrozole alone; IQR = Interquartile Range
Conclusions
The first comparative analysis of a CDK4/6 inhibitor in combination with endocrine therapy compared to endocrine therapy alone provides real-world evidence confirming the findings of PFS benefit demonstrated in clinical trial data for palbociclib in diverse clinical practices.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Pfizer Inc.
Funding
Pfizer Inc.
Disclosure
R.M. Layman: Research grant / Funding (institution): Pfizer Inc. X. Liu: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer Inc. J. Mardekian: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer Inc. L. McRoy: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer Inc.
Resources from the same session
2686 - Clinicopathological characteristics, survival and prognostic factors of breast cancer-related microangiopathic haemolytic anemia: a multicenter study
Presenter: Marion Alhenc Gelas
Session: Poster Display session 2
Resources:
Abstract
1565 - Metabolic tumor volume by 18F-FDG PET/CT is an independent prognostic factor in metastatic breast cancer
Presenter: Heekyung Ahn
Session: Poster Display session 2
Resources:
Abstract
4498 - Patient Preferences for breast cancer treatments: A Discrete Choice Experiment from four European countries
Presenter: Thomais Konstantopoulou
Session: Poster Display session 2
Resources:
Abstract
1423 - Palbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study
Presenter: Diana Lüftner
Session: Poster Display session 2
Resources:
Abstract
2284 - Ventriculoperitoneal Shunt for CNS Metastasis in Breast Cancer: Clinical Outcomes Based on Intrinsic Subtype
Presenter: Hee Kyung Kim
Session: Poster Display session 2
Resources:
Abstract
4598 - Administration of chemotherapy for metastatic breast cancer near the end of life: a population registry study
Presenter: Luisa Edman Kessler
Session: Poster Display session 2
Resources:
Abstract
5706 - Prognostic value of histological growth pattern in patients operated for breast cancer liver metastases
Presenter: Ali Bohlok
Session: Poster Display session 2
Resources:
Abstract
1697 - Illness perceptions, quality of life and mood in metastatic breast cancer patients
Presenter: Isabel Domingues
Session: Poster Display session 2
Resources:
Abstract
1935 - Multidisciplinary Treatments Increases Overall Survival in Patients with Newly Diagnosed Stage IV Breast Cancer:An Analysis of 2010–2014 SEER Data
Presenter: Jian Zhang
Session: Poster Display session 2
Resources:
Abstract
3875 - Correlation of radiotherapy with the prognosis of elderly patients with hormone receptor-positive breast cancer according to immunohistochemical subtyping
Presenter: Jin Zhang
Session: Poster Display session 2
Resources:
Abstract